Next, for each tumor type, we again utilized the ZNF154 beta value hypermethylation cutoff sufficient to exclude 95% of control samples and compared the percentage of tumors with ZNF154 hypermethylation with the percentage of tumors that harbored any cancer-associated gene mutation in the given cancer-type gene set (Fig. 1). This evidence concerns the gene ZNF154 and neoplasm.